Cerivastatin Induces Carotid Artery Plaque Stabilization Independently of Cholesterol Lowering in Patients with Hypercholesterolaemia
Authors:
- 1 August 2001
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 29 (4) , 329-334
Abstract
To prevent cardiovascular events in hyperlipidaemic patients, plaque stabilization by inhibition of localized inflammatory reactions in the blood vessels is important in addition to cholesterol lowering. Cerivastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (statin), has more potent enzyme-inhibitory effects than other statins and has also been reported in vitro to inhibit, at low concentrations, various inflammatory reactions due to plaque instability. Cerivastatin was therefore administered over 12 months to five patients with hypercholesterolaemia and atherosclerotic plaque diagnosed by ultrasonography of the carotid artery, and changes in the plaque composition were determined. The mean cholesterol level decreased over the study period, although not significantly. However, the mean percentage of fibrous matrix of the plaque increased significantly from a mean of 11.2 ± 7.7% at study entry to 18.3 ± 5.9% at the end of the study. Additionally, the mean maximum plaque height was significantly reduced from 3.7 ± 0.9 mm to 3.0 ± 0.7 mm. These results indicate that cerivastatin induces plaque stability independently of cholesterol lowering.Keywords
This publication has 8 references indexed in Scilit:
- An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In VitroCirculation, 2001
- Effects of Cerivastatin on Human Arterial Smooth Muscle Cell Proliferation and Migration in Transfilter CoculturesJournal of Cardiovascular Pharmacology, 2000
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Relationship Between Plasma LDL Concentrations During Treatment With Pravastatin and Recurrent Coronary Events in the Cholesterol and Recurrent Events TrialCirculation, 1998
- Suppression of neointimal thickening by a newly developed HMG‐CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growthBritish Journal of Pharmacology, 1997
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.Circulation, 1994